Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Publication year range
1.
Rev. méd. Paraná ; 80(1): 1-2, jan. 2022.
Article in Portuguese | LILACS | ID: biblio-1381020

ABSTRACT

As plantas medicinais são de fácil aquisição sem receita médica. Algumas delas possuem comprovação científica para o efeito hipoglicemiante, outras não. O objetivo deste estudo foi conhecer a prevalência e o perfil do paciente que usa plantas medicinais como coadjuvantes no tratamento do diabete. Foram entrevistados 140 diabéticos e pré-diabéticos agrupados em quem fazia o uso dessa alternativa e os que não. Em conclusão, a prevalência foi de 15,7%, maior em mulheres. A medicação prescrita foi metformina. A planta mais utilizada foi a pata-de-vaca. O grupo em uso referiu melhora glicêmica com a terapia complementar quando questionados sobre a glicemia uma semana antes e na semana de uso


Medicinal plants are easily available without a prescription. Some of them have scientific proof for the hypoglycemic effect, others do not. The objective of this study was to know the prevalence and profile of patients who use medicinal plants as adjuncts in the treatment of diabetes. A total of 140 diabetics and pre-diabetics were interviewed, grouped into those who used this alternative and those who did not. In conclusion, the prevalence was 15.7%, higher in women. The medication prescribed was metformin. The most used plant was the pata-de-vaca. The group in use reported glycemic improvement with the complementary therapy when asked about the glycemia one week before and in the week of use


Subject(s)
Adult , Plants, Medicinal , Therapeutics , Diabetes Mellitus , Phytotherapy , Metformin
2.
Preprint in Portuguese | SciELO Preprints | ID: pps-4150

ABSTRACT

Background: Papillary thyroid carcinomas (PTC) are the most prevalent and least aggressive thyroid carcinomas. In some cases, the diagnosis is doubtfull and the prognosis is poor. The search for tissue biomarkers that make it possible to ensure both the diagnosis for indeterminate cases and the prognosis, identifying the most aggressive cases, has been studied in recent decades. Objective: To analyze the molecular marker cyclin D1 in PTC and multinodular goiter (BMN) and to verify the correlation of the marking with the clinical-pathological characteristics in carcinomas. Methods: 118 tissues from adult patients submitted to PTC thyroidectomy and 40 BMN were selected as a control group. Tissue immunostaining was performed with cyclin D1 with subsequent immunohistochemical analysis in both groups, evaluating the expression of the marker (intensity and distribution). In the PTC group, immunostaining data were also crossed with clinical and pathological data. Results: The majority (93.3%) expressed the staining of cyclin D1 with varying intensities (weak, moderate 3 and strong) and predominantly diffuse distribution (71.2%). The BMN control group expressed staining for cyclin D1 in 57.5%, with weak intensity (47.5%) and sparse distribution (37.5%). The difference between the groups (study and control) was statistically significant (p<0.001). In the CPT group, the clinical-pathological crossings did not show differences regarding age, sex, tumor type and size, lymph node status, focus, angiolymphatic invasion. Conclusion: Cyclin D1 was expressed in the vast majority of PTC with the predominant diffuse distribution. There was no correlation between the expression of cyclin D1 and any clinical-pathological characteristic of PTC.


Racional - Os carcinomas papilíferos são os mais prevalentes e menos agressivos de tireoide (CPT). Em alguns casos, o diagnóstico é duvidoso e o prognóstico ruim. A busca de biomarcadores teciduais que permitam assegurar tanto o diagnóstico para casos indeterminados, quanto o prognóstico, identificando os casos de maior agressividade, têm sido estudadas nas últimas décadas. Objetivo: Analisar a ciclina D1 nos CPT e nos bócios multinodulares (BMN) e verificar a correlação da marcação com as características clinicopatológicas. Métodos: Foram selecionados 118 tecidos de pacientes adultos submetidos àa tireoidectomia por CPT e 40 BMN como grupo controle. Realizou-se imunocoloração tecidual com ciclina D1 com subsequente análise imunoistoquímica em ambos grupos, avaliando-se a expressão do marcador (intensidade e distribuição). No grupo dos CPT os dados da imunocoloração foram também cruzados com os dados clinicopatológicos. Resultados: A maioria (93,3%) expressou a coloração da ciclina D1 com intensidades variadas (fraca, moderada e forte) e distribuição predominantemente difusa (71,2%). O grupo controle dos BMN, expressou coloração para ciclina D1 em 57,5%, com intensidade fraca (47,5%) e distribuição esparsa (37,5%). A diferença entre os grupos (estudo e controle) foi estatisticamente significante (p<0,001). No grupo dos CPT, os cruzamentos clinicopatológicos não evidenciaram diferenças quanto à idade, sexo, tipo e tamanho tumoral, estado linfonodal, focalidade e invasão angiolinfática. Conclusão: A ciclina D1 foi expressa na grande maioria dos CPT sendo a distribuição difusa predominante. Não houve correlação entre a expressão delacom qualquer característica clinicopatológica dos CPT.

3.
Rev Assoc Med Bras (1992) ; 68(3): 400-404, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35442371

ABSTRACT

OBJECTIVE: Thyroid neoplasm incidence has increased worldwide, mostly due to the advancements in medical imaging and screening rates. The aberrant Wnt/ß-catenin pathway has been identified as a key mechanism, and it has also been related to the metastatic activity of differentiated thyroid cancer. We aimed to verify the difference in the expression of Wnt3a, a canonical activator of the ß-catenin signaling, and CDX-2, a transcription factor upregulated by Wnt/ß-catenin pathway, in multinodular goiter and differentiated thyroid cancer and to determine their prognostic value. METHODS: We included 194 thyroid tissue surgical specimen and their clinicopathological data: study group (differentiated thyroid cancer, n=154) and control group (multinodular goiter, n=40). Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded tissue by the primary antibodies Wnt3a and CDX-2. RESULTS: High Wnt3a expression was significantly associated with differentiated thyroid cancer (p=0.031). CDX-2 was negative in all differentiated thyroid cancer cases (100%) and also in multinodular goiter. Wnt3a expression was significantly associated with tumors ≤20 mm (p=0.044) and with the absence of capsule invasion (p=0.031). The multivariate analyses suggested that older age (≥55), independent of capsular invasion and tumor size, was an independent prognostic factor for Wnt3a expression (p=0.058). CONCLUSIONS: Wnt3a expression but not CDX-2 is correlated with differentiated thyroid cancer samples in comparison to multinodular goiter. Although its prognostic value was limited to tumor size and capsule invasion, a combined model in a panel of immune markers can add accuracy in the classification of challenging thyroid follicular-derived lesions.


Subject(s)
Adenocarcinoma , Thyroid Neoplasms , Wnt3A Protein , Adenocarcinoma/pathology , CDX2 Transcription Factor , Goiter , Humans , Thyroid Neoplasms/pathology , Wnt Signaling Pathway , Wnt3A Protein/metabolism , beta Catenin/metabolism
4.
Rev. Assoc. Med. Bras. (1992) ; 68(3): 400-404, Mar. 2022. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1376131

ABSTRACT

SUMMARY OBJECTIVE: Thyroid neoplasm incidence has increased worldwide, mostly due to the advancements in medical imaging and screening rates. The aberrant Wnt/β-catenin pathway has been identified as a key mechanism, and it has also been related to the metastatic activity of differentiated thyroid cancer. We aimed to verify the difference in the expression of Wnt3a, a canonical activator of the β-catenin signaling, and CDX-2, a transcription factor upregulated by Wnt/β-catenin pathway, in multinodular goiter and differentiated thyroid cancer and to determine their prognostic value. METHODS: We included 194 thyroid tissue surgical specimen and their clinicopathological data: study group (differentiated thyroid cancer, n=154) and control group (multinodular goiter, n=40). Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded tissue by the primary antibodies Wnt3a and CDX-2. RESULTS: High Wnt3a expression was significantly associated with differentiated thyroid cancer (p=0.031). CDX-2 was negative in all differentiated thyroid cancer cases (100%) and also in multinodular goiter. Wnt3a expression was significantly associated with tumors ≤20 mm (p=0.044) and with the absence of capsule invasion (p=0.031). The multivariate analyses suggested that older age (≥55), independent of capsular invasion and tumor size, was an independent prognostic factor for Wnt3a expression (p=0.058). CONCLUSIONS: Wnt3a expression but not CDX-2 is correlated with differentiated thyroid cancer samples in comparison to multinodular goiter. Although its prognostic value was limited to tumor size and capsule invasion, a combined model in a panel of immune markers can add accuracy in the classification of challenging thyroid follicular-derived lesions.

5.
BioSC. (Curitiba, Impresso) ; 80(2): 51-53, 20220000.
Article in Portuguese | LILACS | ID: biblio-1438537

ABSTRACT

Introdução: A intolerância à lactose é síndrome decorrente da má digestão do dissacarídeo lactose por deficiência da enzima lactase, gerando sintomas principalmente gastrintestinais. Ela envolve 4 causas principais: deficiência congênita de lactase; deficiência de lactase de desenvolvimento; intolerância primária à lactose; e deficiência secundária à lactase. Objetivo: Revisão da apresentação clínica da intolerância à lactose e os principais métodos disponíveis para seu diagnóstico clínico. Método: Revisão narrativa da base de dados PubMed, por meio das palavras-chave "lactose intolerance" e "genetic test" utilizando o descritor boleano and. Foram incluídos somente artigos em língua inglesa e publicados entre os anos de 2017 e 2022, totalizando 8 artigos. Resultado: O diagnóstico de intolerância à lactose relaciona-se com o seu tipo e utiliza-se dos principais métodos: teste oral de tolerância à lactose, teste genético, teste do hidrogênio expirado. Conclusão: Quanto aos métodos de diagnóstico, o teste do hidrogênio expirado é o de escolha, por não ser invasivo, possuir execução fácil e baixo custo. Entretanto, ele não dispensa associação com outras técnicas diagnósticas. O teste genético também é muito útil e sua vantagem é que não há necessidade da realização do teste oral de tolerância.


Introduction: Lactose intolerance is a syndrome resulting from maldigestion of the disaccharide lactose due to lactase enzyme deficiency causing symptoms mainly gastrointestinal. It involves 4 main causes: congenital lactase deficiency; developmental lactase deficiency; primary lactose intolerance; and secondary lactase deficiency. Objective: Review of the clinical presentation of lactose intolerance and the main methods available for its clinical diagnosis. Methods: Literature review in the PubMed database, using the keywords "lactose intolerance" and "genetic test" and using the Boolean data type and. Only articles in English and published between the years 2017 and 2022 were included, totalizing 8 articles. Results: The diagnosis of lactose intolerance is related to its type and uses the main diagnostic tests: oral lactose tolerance, genetic, expired hydrogen. Conclusion: Regarding diagnostic methods, the expired hydrogen test is the one of choice, as it is not invasive, is easy to perform and has low cost. However, it does not dispense association with other diagnostic techniques. Genetic testing is also very usefull and its advantage is that there is no need to use the oral lactose tolerance test.

6.
BioSC. (Curitiba, Impresso) ; 80(Supl.1): 33-35, 20220000.
Article in Portuguese | LILACS | ID: biblio-1417793

ABSTRACT

Ainda não existe consenso a respeito da prescrição de testosterona terapêutica para mulheres cisgênero na menopausa, seus benefícios e efeitos colaterais. Objetivo: Sumarizar os estudos recentes sobre o uso terapêutico da testosterona em mulheres na menopausa. Método: Revisão sistemática de literatura baseada nos dados da plataforma PubMed. Foram identificados 10.912 estudos potenciais. As palavras-chave usadas foram "testosterone", "women", "therapy", "treatment". Selecionou-se revisões sistemáticas e metanálises dos últimos 5 anos, todas na língua inglesa. Excluiram-se artigos duplicados, os que abordam uso de testosterona como anabolizantes e/ou em atletas e em transexuais e estudos que envolviam homens. O levantamento de dados foi realizado com 9 artigos. Resultados: O uso dessa terapia hormonal no período da pós-menopausa mostrou melhora dos sintomas sexuais. Há diferença entre as vias de aplicação, sendo que a via oral pode acarretar maiores prejuízos, principalmente em relação aos níveis lipídicos séricos. A testosterona intravaginal melhora a função sexual. A prescrição na prática se mostra um problema, pois as apresentações comercializadas não atendem à necessidade fisiológica feminina. Conclusão: A terapia mostra-se eficaz em curto prazo, apesar de ainda haver necessidade de estudos para uso em longo prazo


There is still no consensus regarding the prescription of testosterone therapy for cisgender menopausal woman, its benefits and side effects. Objective: Summarize recent studies on the therapeutic use of testosterone in menopausal woman. Methods: Systematic literature review based on data from the PubMed platform. A total of 10.912 potential studies were identified. The used keywords were "testosterone", "woman", "therapy", "treatment". Systematic reviews and meta-analyses from the last 5 years were selected, all in English. Were excluded: duplicated articles, the ones that address the use of testosterone as anabolic steroid and/or in athletes and transsexuals and studies that involved man. Tthe data collection was made with 9 articles. Results: The use of this hormone therapy in postmenopausal period showed sexual symptoms improvement. There are differences between the routes of administration, for the oral administration could lead to more damage, mainly related to the lipids serum levels. Intravaginal testosterone improves sexual function. The prescription in practice is shown to be a problem, since the commercialized presentations do not meet the feminine physiological necessities. Conclusion: This therapy proves to be effective in short term use, although there is still a need for studies for long-term use


Subject(s)
Humans , Female , Middle Aged , Testosterone , Women , Menopause , Hormone Replacement Therapy , Hormones , Dehydroepiandrosterone , Cisgender Persons
SELECTION OF CITATIONS
SEARCH DETAIL
...